Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
Chronic Liver Disease Foundation
Real-world baseline characteristics of patients with obesity or overweight and comorbid MASH receiving semaglutide
Chronic Liver Disease Foundation
CLDF 2025
20 - 22 March 2025
Real-world baseline characteristics of patients with obesity or overweight and comorbid MASH receiving semaglutide
Authors
:
Husam Albarmawi
1
; Alia Yousif
2
; Abdalla Aly
1
; Firas Dabbous
2
; Samuel Huse
2
; Maximilian Kurt Jara
1
Affiliations
View Details
Hide Details
06:12
Download poster (.pdf)
Share
Copy link
{{pageUrl}}
Keywords
MASH
Congress poster
GLP-1 RA
Semaglutide
RWE HEOR